Search | German Center for Infection Research

Jun 2021

PLoS Negl Trop Dis

Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2

Autoren

Nouatin O et al.

May 2021

J Hepatol

Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients

Autoren

Cornberg M

Eberhardt CS

May 2021

Infection

Ensuring global access to COVID-19 vaccines: deployment strategies for refugees and migrants must not be forgotten

Autoren

Buonsenso D

von Both U

Combination vaccines against Covid-19 tested

People under the age of 60 who initially received a vaccine from AstraZeneca should be given an mRNA vaccine at their second appointment. This is recommended by the German Standing Committee on

Study with optimized vector vaccine MVA-SARS-2-S resumed

The clinical review of the MVA-SARS-2-S vector vaccine against COVID-19 will continue with a new version. The DZIF (German Center for Infection Research) scientists temporarily suspended the study

Long-lasting and profound reprogramming of immune cells after COVID-19

SARS-CoV-2 infection causes severe inflammation of the lungs and other vital organs. Why some infected individuals respond with an exaggerated immune response to the virus remains not well understood

Mar 2021

Microbiol Immunol

Rapid prototyping vaccine approach in mice against multi-drug resistant Gram-negative organisms from clinical isolates based on outer membrane vesicles

Autoren

Pritsch M et al.

Apr 2021

Vaccines (Basel)

A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response

Autoren

Lainšček D et al.

Apr 2021

Vaccines (Basel)

Correlates of Vaccine-Induced Protection against SARS-CoV-2

Autoren

Koch T et al.

SARS-CoV-2: A computer model to visualise possible attack points of viruses and virus mutants

There is still an urgent need for drugs against the new coronavirus. This urgency increases further with the emergence of new virus mutations that could push vaccines to their limits. For more than a